NCT06879002

Comparing IVF/ICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol With Elonva Without GnRH Antagonist to Follicular Phase Day 2 Stimulation Fixed Day 5 Antagonist Protocol

To Compare IVF/ICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol With Elonva Without GnRH Antagonist to Follicular Phase Fixed Day 5 Antagonist Protocol

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 252 (estimated)
• Sponsor: ART Fertility Clinics LLC · Academic / Other
• Sex: Female
• Age: 18 Years – 38 Years
• Healthy volunteers: Accepted

Summary

There are several approaches to the timing of antagonist administration in IVF/ICSI cycles. The primary goal is indeed to prevent premature ovulation, which could jeopardize the success of the cycle There is an emerging concept that suggests that the progesterone produced by the corpus luteum (formed after ovulation) might be sufficient to prevent further ovulation, obviating the need for antagonist or exogenous progesterone administration. This hypothesis relies on the natural regulatory mechanisms of the menstrual cycle to maintain a progesterone-dominated environment post-ovulation. We hypothesized that this approach would minimize treatment costs /burden without having an impact on the outcome.

Conditions

• Stimulation in the Ovary
• IVF Outcome

Interventions

Type	Name	Description
OTHER	Ovarian stimulation with menstruation or after ovulation	Ovarian stimulation with menstruation or after ovulation

Timeline

• Start date: 2025-12-30
• Primary completion: 2026-04-30
• Completion: 2026-12-30
• First posted: 2025-03-17
• Last updated: 2025-10-02

Locations

2 sites across 1 country: United Arab Emirates